{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:04:49Z","timestamp":1767211489168,"version":"3.48.0"},"reference-count":41,"publisher":"Akademiai Kiado Zrt.","issue":"4","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["EuJMI"],"published-print":{"date-parts":[[2025,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mouse Integrin Associated Protein (MIAP) monoclonal antibodies are widely used for immunotherapeutic blockade of CD47. The anti-CD47 clones MIAP301 and MIAP410 have been studied as an immunotherapeutic treatment in the context of cancer and infectious diseases. To investigate the degree of induction of immune response afforded by these anti-CD47 clones, we treated C57BL\/6 mice with MIAP301 or MIAP410, or isotype for two days and infected them with lymphocytic choriomeningitis virus (LCMV). We found that the treatment of MIAP301 led to a significant increase in mRNA expression of\n                    <jats:italic>IFN\u03b14<\/jats:italic>\n                    and\n                    <jats:italic>IFN\u03b21<\/jats:italic>\n                    compared to MIAP410 or isotype. Our study further revealed that MIAP301 treatment enhanced the numbers of CD11b\n                    <jats:sup>+<\/jats:sup>\n                    macrophages and CD11c\n                    <jats:sup>+<\/jats:sup>\n                    dendritic cells, as well as improved phagocytic capacity. Analysis of NK and T cells showed a subtle difference, and a significantly increased IFN-\u03b3\n                    <jats:sup>+<\/jats:sup>\n                    NK cell in the mice treated with MIAP301. Both anti-CD47 antibodies significantly increased NK cells, CD8\n                    <jats:sup>+<\/jats:sup>\n                    , and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells quantity and quality when compared to isotype. Overall, our findings indicate that MIAP301 treatment significantly increases myeloid innate immune signaling compared to MIAP410 treatment. Considering the evolving preclinical studies using anti-CD47 for therapy, our study findings may be important when deciding which clone to use.\n                  <\/jats:p>","DOI":"10.1556\/1886.2025.00065","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T07:37:41Z","timestamp":1764661061000},"page":"240-247","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["CD47 monoclonal antibodies differ in their capacity to induce immune response"],"prefix":"10.1556","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-5657","authenticated-orcid":true,"given":"Lamin B.","family":"Cham","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Health Sciences, Arabian Gulf University, 26671 Manama, Bahrain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalnar","family":"Albaloshi","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Health Sciences, Arabian Gulf University, 26671 Manama, Bahrain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alhussain","family":"Alnakhli","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Health Sciences, Arabian Gulf University, 26671 Manama, Bahrain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Farid","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Health Sciences, Arabian Gulf University, 26671 Manama, Bahrain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamer A.","family":"Hamdan","sequence":"additional","affiliation":[{"name":"Department of Basic Dental Sciences, Faculty of Dentistry, Al-Ahliyya Amman University, 19328 Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Adomati","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, B-2610 Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed-Ridha","family":"Barbouche","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Health Sciences, Arabian Gulf University, 26671 Manama, Bahrain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"B1","series-title":"ISRN Hematol","article-title":"CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease","volume":"2013","author":"Oldenborg PA","year":"2013","unstructured":"Oldenborg PA. CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease. ISRN Hematol. 2013;2013:614619."},{"issue":"3","key":"B2","series-title":"mBio","article-title":"Upregulation of CD47 is a host checkpoint response to pathogen recognition","volume":"11","author":"Tal MC","year":"2020","unstructured":"Tal MC, Dulgeroff LBT, Myers L, Cham LB, Mayer-Barber KD, Bohrer AC, et\u00a0al. Upregulation of CD47 is a host checkpoint response to pathogen recognition. mBio. 2020;11(3):e01293-20."},{"issue":"3","key":"B3","series-title":"Nat Cancer","first-page":"500","article-title":"Sirpalpha on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47","volume":"5","author":"Huang C","year":"2024","unstructured":"Huang C, Wang X, Wang Y, Feng Y, Wang X, Chen S, et\u00a0al. Sirpalpha on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47. Nat Cancer. 2024;5(3):500\u201316."},{"issue":"1","key":"B4","series-title":"Nat Commun","first-page":"794","article-title":"A functional subset of CD8(+) T cells during chronic exhaustion is defined by SIRPalpha expression","volume":"10","author":"Myers LM","year":"2019","unstructured":"Myers LM, Tal MC, Dulgeroff LBT, Carmody AB, Messer RJ, Gulati G, et\u00a0al. A functional subset of CD8(+) T cells during chronic exhaustion is defined by SIRPalpha expression. Nat Commun. 2019;10(1):794."},{"issue":"6","key":"B5","series-title":"Matrix Biol","first-page":"316","article-title":"Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation","volume":"32","author":"Miller TW","year":"2013","unstructured":"Miller TW, Kaur S, Ivins-O'Keefe K, Roberts DD. Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol. 2013;32(6):316\u201324."},{"issue":"17","key":"B6","series-title":"Proc Natl Acad Sci U S A","first-page":"6662","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham SB","year":"2012","unstructured":"Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et\u00a0al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662\u20137."},{"key":"B7","series-title":"Annu Rev Immunol","first-page":"25","article-title":"The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay AN","year":"2014","unstructured":"Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol. 2014;32:25\u201350."},{"issue":"10","key":"B8","series-title":"Cell Death Differ","first-page":"1255","article-title":"Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity","volume":"31","author":"Polara R","year":"2024","unstructured":"Polara R, Ganesan R, Pitson SM, Robinson N. Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity. Cell Death Differ. 2024;31(10):1255\u201366."},{"issue":"4","key":"B9","series-title":"Cell Physiol Biochem","first-page":"322","article-title":"Single-cell analysis reveals that CD47 mRNA expression correlates with immune cell activation, antiviral Isgs, and cytotoxicity","volume":"58","author":"Cham LB","year":"2024","unstructured":"Cham LB, Rosas-Umbert M, Lin L, Tolstrup M, S\u00f8gaard OS. Single-cell analysis reveals that CD47 mRNA expression correlates with immune cell activation, antiviral Isgs, and cytotoxicity. Cell Physiol Biochem. 2024;58(4):322\u201335."},{"issue":"5473","key":"B10","series-title":"Science","first-page":"2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg PA","year":"2000","unstructured":"Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresahm HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051\u20134."},{"issue":"12","key":"B11","series-title":"Transl Oncol","article-title":"Regulation of CD47 expression in cancer cells","volume":"13","author":"Huang C-Y","year":"2020","unstructured":"Huang C-Y, Ye Z-H, Huang M-Y, Lu J-J. Regulation of CD47 expression in cancer cells. Transl Oncol. 2020;13(12):100862."},{"issue":"2","key":"B12","series-title":"Curr Opin Immunol","first-page":"225","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao MP","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225\u201332."},{"key":"B13","series-title":"J Adv Res","first-page":"129","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu Y","year":"2024","unstructured":"Liu Y, Weng L, Wang Y, Zhang J, Wu Q, Zhao P, et\u00a0al. Deciphering the role of CD47 in cancer immunotherapy. J Adv Res. 2024;63:129\u201358."},{"issue":"1","key":"B14","series-title":"Signal Transduct Target Ther","first-page":"104","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu Y","year":"2023","unstructured":"Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, et\u00a0al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8(1):104."},{"issue":"2","key":"B15","series-title":"Cell Rep","article-title":"Immunotherapeutic blockade of CD47 inhibitory signaling enhances innate and adaptive immune responses to viral infection","volume":"31","author":"Cham LB","year":"2020","unstructured":"Cham LB, Dulgeroff LBT, Tal MC, Adomati T, Li F, Bhat H, et\u00a0al. Immunotherapeutic blockade of CD47 inhibitory signaling enhances innate and adaptive immune responses to viral infection. Cell Rep. 2020;31(2):107494."},{"issue":"3","key":"B16","series-title":"Antibodies (Basel)","first-page":"44","article-title":"CD47 as a potential target to therapy for infectious diseases","volume":"9","author":"Cham LB","year":"2020","unstructured":"Cham LB, Adomati T, Li F, Ali M, Lang KS. CD47 as a potential target to therapy for infectious diseases. Antibodies (Basel). 2020;9(3):44."},{"issue":"8","key":"B17","series-title":"Int J Mol Sci","article-title":"Thrombospondin-1 CD47 signalling: from mechanisms to medicine","volume":"22","author":"Kale A","year":"2021","unstructured":"Kale A, Rogers NM, Ghimire K. Thrombospondin-1 CD47 signalling: from mechanisms to medicine. Int J Mol Sci. 2021;22(8)."},{"issue":"11","key":"B18","series-title":"J\u00a0Immunother Cancer","article-title":"Targeting the CD47\/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response","volume":"10","author":"Stirling ER","year":"2022","unstructured":"Stirling ER, Terabe M, Wilson AS, Kosshki M, Yamaleyeva LM, Alexander-Miller MA, et\u00a0al. Targeting the CD47\/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response. J\u00a0Immunother Cancer. 2022;10(11):e004712."},{"issue":"8","key":"B19","series-title":"Clin Transl Med","article-title":"CD47-SIRPalpha blocking-based immunotherapy: current and prospective therapeutic strategies","volume":"12","author":"Bouwstra R","year":"2022","unstructured":"Bouwstra R, van Meerten T, Bremer E. CD47-SIRPalpha blocking-based immunotherapy: current and prospective therapeutic strategies. Clin Transl Med. 2022;12(8):e943."},{"issue":"1","key":"B20","series-title":"Oncol Res","first-page":"49","article-title":"Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen Q","year":"2023","unstructured":"Chen Q, Guo X, Ma W. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncol Res. 2023;32(1):49\u201360."},{"key":"B21","series-title":"Elife","article-title":"Chromosomal instability induced in cancer can enhance macrophage-initiated immune responses that include anti-tumor IgG","volume":"12","author":"Hayes BH","year":"2024","unstructured":"Hayes BH, Wang M, Zhu H, Phan SH, Dooling LJ, Andrechak JC, et\u00a0al. Chromosomal instability induced in cancer can enhance macrophage-initiated immune responses that include anti-tumor IgG. Elife. 2024;12: RP88054."},{"issue":"4","key":"B22","series-title":"Pharmaceuticals (Basel)","first-page":"142","article-title":"Tamoxifen protects from vesicular Stomatitis virus infection","volume":"12","author":"Cham LB","year":"2019","unstructured":"Cham LB, Friedrich S-K, Adomati T, Bhat H, Schiller M, Bergerhausen M, et\u00a0al. Tamoxifen protects from vesicular Stomatitis virus infection. Pharmaceuticals (Basel). 2019;12(4):142."},{"issue":"5","key":"B23","series-title":"Cell Physiol Biochem","first-page":"652","article-title":"SIRPalpha is an inhibitory receptor that regulates NK cell activation and function","volume":"59","author":"Cham LB","year":"2025","unstructured":"Cham LB, Hamdan TA, Bhat H, Tabbara KS, Farid E, Barbouche MR, et\u00a0al. SIRPalpha is an inhibitory receptor that regulates NK cell activation and function. Cell Physiol Biochem. 2025;59(5):652\u201365."},{"issue":"2","key":"B24","series-title":"Cancer Pathog Ther","first-page":"116","article-title":"Role of T cells in cancer immunotherapy: opportunities and challenges","volume":"1","author":"Ahmed H","year":"2023","unstructured":"Ahmed H, Mahmoud AR, Faijanur-Rob-Siddiquee M, Shahriar A, Biswas P, Shimul MEK, et\u00a0al. Role of T cells in cancer immunotherapy: opportunities and challenges. Cancer Pathog Ther. 2023;1(2):116\u201326."},{"issue":"3","key":"B25","series-title":"J\u00a0Biol Chem","first-page":"1805","article-title":"Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity. Implications for the binding site","volume":"282","author":"Subramanian S","year":"2007","unstructured":"Subramanian S, Boder ET, Discher DE. Phylogenetic divergence of CD47 interactions with human signal regulatory protein alpha reveals locus of species specificity. Implications for the binding site. J\u00a0Biol Chem. 2007;282(3):1805\u201318."},{"issue":"5","key":"B26","series-title":"Anim Cells Syst (Seoul)","first-page":"243","article-title":"CD47 (Cluster of differentiation 47): an anti-phagocytic receptor with a multitude of signaling functions","volume":"24","author":"Leclair P","year":"2020","unstructured":"Leclair P, Lim CJ. CD47 (Cluster of differentiation 47): an anti-phagocytic receptor with a multitude of signaling functions. Anim Cells Syst (Seoul). 2020;24(5):243\u201352."},{"issue":"1","key":"B27","series-title":"Curr Opin Immunol","first-page":"47","article-title":"Signal regulatory protein alpha (SIRPalpha)\/CD47 interaction and function","volume":"21","author":"Barclay AN","year":"2009","unstructured":"Barclay AN Signal regulatory protein alpha (SIRPalpha)\/CD47 interaction and function. Curr Opin Immunol. 2009;21(1):47\u201352."},{"issue":"4","key":"B28","series-title":"Oncoimmunology","first-page":"e1397248","article-title":"Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma","volume":"7","author":"Wu L","year":"2018","unstructured":"Wu L, Yu G-T, Deng W-W, Mao L, Yang L-L, Ma S-R, et\u00a0al. Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma. Oncoimmunology. 2018;7(4):e1397248."},{"issue":"2","key":"B29","series-title":"J Hepatol","first-page":"467","article-title":"Blocking CD47 promotes antitumour immunity through CD103(+) dendritic cell-NK cell axis in murine hepatocellular carcinoma model","volume":"77","author":"Wang S","year":"2022","unstructured":"Wang S, Wu Q, Chen T, Su R, Pan C, Qian J, et\u00a0al. Blocking CD47 promotes antitumour immunity through CD103(+) dendritic cell-NK cell axis in murine hepatocellular carcinoma model. J Hepatol. 2022;77(2):467\u201378."},{"issue":"17","key":"B30","series-title":"Blood Adv","first-page":"2230","article-title":"Enhancing immunotherapy of STING agonist for lymphoma in preclinical models","volume":"2","author":"Sallets A","year":"2018","unstructured":"Sallets A, Robinson S, Kardosh A, Levy R. Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. Blood Adv. 2018;2(17):2230\u201341."},{"issue":"10","key":"B31","series-title":"Nat Med","first-page":"1209","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu X","year":"2015","unstructured":"Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, et\u00a0al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209\u201315."},{"issue":"2","key":"B32","series-title":"Immunity","first-page":"363","article-title":"Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling","volume":"47","author":"Xu MM","year":"2017","unstructured":"Xu MM, Pu Y, Han D, Shi Y, Cao X, Liang H, et\u00a0al. Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 2017;47(2):363\u201373 e5."},{"issue":"1","key":"B33","series-title":"Biomark Res","first-page":"15","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang H","year":"2023","unstructured":"Yang H, Xun Y, You H. The landscape overview of CD47-based immunotherapy for hematological malignancies. Biomark Res. 2023;11(1):15."},{"issue":"3","key":"B34","series-title":"Antib Ther","first-page":"179","article-title":"Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment","volume":"3","author":"Kaur S","year":"2020","unstructured":"Kaur S, Cicalese KV, Bannerjee R, Roberts DD. Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment. Antib Ther. 2020;3(3):179\u201392."},{"issue":"7614","key":"B35","series-title":"Nature","first-page":"86","article-title":"CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis","volume":"536","author":"Kojima Y","year":"2016","unstructured":"Kojima Y, Volkmer J-P, McKenna K, Civelek M, Lusis AJ, Miller CL, et\u00a0al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536(7614):86\u201390."},{"issue":"4","key":"B36","series-title":"Cancers (Basel)","first-page":"832","article-title":"The combination of anti-CD47 antibody with CTLA4 blockade enhances anti-tumor immunity in non-small cell lung cancer via normalization of tumor vasculature and reprogramming of the immune microenvironment","volume":"16","author":"Zhuang Z","year":"2024","unstructured":"Zhuang Z, Zhou J, Qiu M, Li J, Lin Z, Yi H, et\u00a0al. The combination of anti-CD47 antibody with CTLA4 blockade enhances anti-tumor immunity in non-small cell lung cancer via normalization of tumor vasculature and reprogramming of the immune microenvironment. Cancers (Basel). 2024;16(4):832."},{"issue":"1","key":"B37","series-title":"Nat Commun","first-page":"1508","article-title":"Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity","volume":"11","author":"von Roemeling CA","year":"2020","unstructured":"von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et\u00a0al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11(1):1508."},{"issue":"4","key":"B38","series-title":"Acta Pharm Sin B","first-page":"1467","article-title":"Building on the backbone of CD47-based therapy in cancer: combination strategies, mechanisms, and future perspectives","volume":"13","author":"Ye Z-H","year":"2023","unstructured":"Ye Z-H, Yu W-B, Huang M-Y, Chen J, Lu J-J. Building on the backbone of CD47-based therapy in cancer: combination strategies, mechanisms, and future perspectives. Acta Pharm Sin B. 2023;13(4):1467\u201387."},{"issue":"12","key":"B39","series-title":"iScience","article-title":"Translating CD47-targeted therapy in gastrointestinal cancers: insights from preclinical to clinical studies","volume":"27","author":"Chen C","year":"2024","unstructured":"Chen C, Lu F, Huang H, Pan Y. Translating CD47-targeted therapy in gastrointestinal cancers: insights from preclinical to clinical studies. iScience. 2024;27(12):111478."},{"key":"B40","series-title":"Front Immunol","article-title":"Opportunities and challenges for anti-CD47 antibodies in hematologi cal malignancies","volume":"15","author":"Xu Y","year":"2024","unstructured":"Xu Y, Jiang P, Xu Z, Ye H. Opportunities and challenges for anti-CD47 antibodies in hematologi cal malignancies. Front Immunol. 2024;15:1348852."},{"issue":"1","key":"B41","series-title":"Nat Commun","first-page":"5004","article-title":"Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo","volume":"10","author":"Reed M","year":"2019","unstructured":"Reed M, Luissint A-C, Azcutia V, Fan S, O'Leary MN, Quiros M, et\u00a0al. Epithelial CD47 is critical for mucosal repair in the murine intestine in vivo. Nat Commun. 2019;10(1):5004."}],"container-title":["European Journal of Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/1886\/15\/4\/article-p240.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1886\/15\/4\/article-p240.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1886\/15\/4\/article-p240.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:00:15Z","timestamp":1765879215000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/1886\/15\/4\/article-p240.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":41,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1556\/1886.2025.00065","relation":{},"ISSN":["2062-509X","2062-8633"],"issn-type":[{"type":"print","value":"2062-509X"},{"type":"electronic","value":"2062-8633"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}